How Much Does Mounjaro Cost in 2026?

There is no single price for Mounjaro. There are five, and which one applies to you depends almost entirely on what kind of insurance you have.

The anchor number is the list price: $1,112.16 for a 28-day supply (verified 2026-09-14), which is four single-dose pens, and it is the same at every strength from 2.5 mg to 15 mg [1]. Almost nobody pays it.

Here is the 2026 map, with the source behind each figure. None of this is medical advice. Mounjaro is approved for type 2 diabetes, and whether it is right for you is a conversation with a healthcare provider.

What is Mounjaro’s list price, and has it changed?

Eli Lilly’s own consumer pricing page states the list price of Mounjaro is $1,112.16 per fill, with the wholesale acquisition cost sourced to AnalySource as of January 1, 2026 [1]. A fill is defined as a month’s supply, four pens.

That is up from the roughly $1,069 figure widely cited during 2025, and from about $1,023 at launch in 2022 [2]. So Lilly raised Mounjaro’s US list price by a few percent on January 1, 2026, a year in which it was simultaneously cutting cash prices on Zepbound.

That combination is not a contradiction. List price and what Lilly actually collects have split apart. In its second quarter of 2026, Lilly reported worldwide revenue up 48% on a 60% volume increase but a 13% decrease in realized prices [3]. Most of that decline is international, driven largely by Mounjaro’s addition to China’s National Reimbursed Drug List; US realized prices fell 3%, or about 9% excluding rebate-estimate adjustments, and Lilly attributed the US decline primarily to Zepbound and Mounjaro [3].

How much is Mounjaro without insurance?

Lilly’s own LillyDirect page shows the same self-pay card at every dose from 2.5 mg through 15 mg, supplied as a single-dose prefilled pen: “Self-pay price: Starting at $499/month” [4]. There is no vial presentation of Mounjaro and no dose-tiered ladder like Zepbound’s, so the price does not climb as you titrate. Read Lilly’s wording literally, though: “starting at” makes $499 a floor rather than a guaranteed flat price, and the page adds that additional taxes and fees may apply.

TrumpRx.gov shows the same thing from the other direction: an original price of $1,112.16, savings of $613.16, a final price of $499.00 and an advertised 55% discount, with the order fulfilled through LillyDirect [5].

This is worth stating plainly because a great deal of content published in the first half of 2026 says there is no Mounjaro self-pay program, or that cash payers pay near list even through LillyDirect. Lilly’s own page and the federal price site both say $499.

Two different $499s, and people confuse them. Verified 2026-09-14, the number appears in two separate Lilly programs, and only one of them is a self-pay price:

• LillyDirect self-pay, $499. Lilly’s LillyDirect Mounjaro page shows “Starting at $499/month” on the card for every strength from 2.5 mg to 15 mg, described as a self-pay price for the single-dose prefilled pen. No insurance is required. This is the $499 TrumpRx routes you to.
• Savings card, non-covered tier, also as low as $499. Lilly’s savings-coverage page sets a separate $499 price for patients who do have commercial drug insurance that does not cover Mounjaro, with maximum savings up to $647 per month and $8,411 per calendar year across up to 13 fills. This tier is closed to the uninsured and to anyone on Medicare, Medicaid, TRICARE or VA coverage.

They land on the same number today, but they are different programs with different eligibility, and only the LillyDirect price is open to someone with no insurance at all.

Adding Mounjaro to LillyDirect at 50% to 60% off list was one of the explicit commitments in Lilly’s November 6, 2025 agreement with the US government [6].

What does a regular pharmacy charge?

If you walk in with no insurance, no coupon and no self-pay card, you are at or near list.

GoodRx puts the average retail price for the most common Mounjaro version at roughly $1,350, with a GoodRx coupon price around $1,086 to $1,096, roughly 19% off [7]. These prices move week to week; check the live figure before relying on it. SingleCare’s July 2026 check in one ZIP code showed $872.48 for four 5 mg pens, with $927.61 at Walgreens, $933.54 at CVS and $953.07 at Walmart [8].

Two things to know about discount cards. They run instead of your insurance, never alongside it, so nothing you spend counts toward a deductible. And they cannot be combined with the Lilly savings card.

The honest summary: shopping pharmacies moves the price by a couple of hundred dollars. Switching to the manufacturer’s own self-pay channel moves it by six hundred.

How does the Mounjaro Savings Card work?

Lilly’s Mounjaro Single-Dose Pen Savings Card has two tiers, and both require commercial drug insurance plus a prescription for type 2 diabetes [9].

Tier one, your plan covers Mounjaro. You may pay as little as $25 for a one-, two- or three-month fill. Savings are capped at $150 per one-month fill, $300 per two months, $450 per three months, and $1,950 per calendar year, across at most 13 fills. A month is 28 days and up to four pens.

Tier two, your plan does not cover Mounjaro. The card sets the price as low as $499 per month, with savings capped at $647 per month and $8,411 per calendar year, again up to 13 fills.

Both tiers expire December 31, 2026.

The eligibility list is strict. You must be 18 or older, a resident of the US or Puerto Rico, and not enrolled in any state, federal or government-funded healthcare program, including Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE or CHAMPUS, or any state prescription drug assistance program [9].

There is one more exclusion worth flagging. If your plan participates in an alternative funding program that requires you to apply to the savings card as a condition of coverage, Lilly’s terms say you are not eligible and are prohibited from using the card [9]. Lilly also reserves the right to reduce or eliminate card savings if your plan removes coverage and pushes you onto the card, or does not apply card payments toward your deductible.

Does Medicare cover Mounjaro?

Yes. Because type 2 diabetes is a covered indication, Mounjaro is an ordinary Part D drug and appears on most Part D and Medicare Advantage drug formularies, typically at a preferred brand tier with prior authorization and quantity limits.

On August 28, 2026 the FDA also approved Mounjaro to reduce the risk of major adverse cardiovascular events, meaning cardiovascular death, non-fatal heart attack or non-fatal stroke, in adults with type 2 diabetes at high risk for them [16]. The approval rests on SURPASS-CVOT, a 13,299-participant head-to-head trial against Trulicity in which Mounjaro was non-inferior, with an 8% lower rate of those events; superiority was not established [16]. This is a second covered indication inside type 2 diabetes, not a route to weight-loss coverage, and it is too new for its effect on formulary placement to be visible yet.

Three things shape what you actually pay:

• The 2026 Part D out-of-pocket cap is $2,100. Once your covered drug spending reaches it, your plan pays the full cost of covered drugs for the rest of the year. The maximum Part D deductible in 2026 is $615.
• You cannot use the Lilly savings card. Government beneficiaries are excluded from every tier [9].
• The Medicare Prescription Payment Plan can smooth the cost. Lilly’s own savings page points Medicare beneficiaries to it. It is a free federal budgeting tool that spreads covered Part D drug costs into fixed monthly payments across the plan year, and you can opt in at any time [9].

One important boundary: the Medicare GLP-1 Bridge, the $50-a-month demonstration that started July 1, 2026, does not cover Mounjaro. It covers Foundayo, Wegovy and the Zepbound KwikPen, and anyone with type 2 diabetes is excluded from it because Part D already provides a pathway.

Looking ahead, CMS’s BALANCE Model does include all formulations of Mounjaro, with Lilly and Novo Nordisk agreeing to a $245 net price per 30-day supply for Medicare in 2027 [10]. The Medicare Part D piece of BALANCE did not launch for 2027 after the 80% plan participation threshold was missed. The Medicaid piece opened to states on a rolling basis from May 1, 2026.

Does Medicaid cover Mounjaro?

Yes, essentially everywhere, for type 2 diabetes.

Under the Medicaid Drug Rebate Program, states must cover nearly all of a participating manufacturer’s FDA-approved drugs for medically accepted indications. Weight-loss drugs are one of the few categories a state may exclude, which is why Zepbound for obesity is optional while Mounjaro for type 2 diabetes is required [11]. Prior authorization and step therapy are common; several states require a trial of metformin and sometimes another agent first.

Medicaid copays are nominal, generally $0 to $8 depending on the state.

Does TRICARE or the VA cover Mounjaro?

TRICARE covers Mounjaro for type 2 diabetes with an approved prior authorization, and that coverage continued unchanged through the 2025 policy shake-up [12]. TRICARE does not cover Mounjaro for weight loss under any plan, because weight loss is not on its label. Weight-loss coverage of Zepbound is limited to TRICARE Prime, Select and premium-based plans; effective August 31, 2025 the Defense Health Agency ended weight-loss drug coverage for TRICARE For Life, direct-care-only, TRICARE Plus, foreign force and NATO beneficiaries, and prior authorizations approved before that date became invalid for those groups [12].

VA treats Mounjaro as a type 2 diabetes drug with its own Criteria for Use, which is stricter than for some alternatives. CHAMPVA, which covers dependents of certain totally disabled veterans, lists Mounjaro for type 2 diabetes and Zepbound for moderate-to-severe obstructive sleep apnea confirmed by a recent sleep study, and does not cover any GLP-1 for weight loss.

Is there a Mounjaro patient assistance program?

Not through Lilly Cares, despite what many websites say.

The Lilly Cares Foundation provides free Lilly medicines for up to 12 months to qualifying patients. Its published medication groups as of September 14, 2026 list Cialis, Emgality, Forteo, Reyvow and Trulicity in Group 1; Basaglar, Humalog, Humulin and Lyumjev in Group 2; and immunology and oncology products in Groups 3 and 4 [13]. Neither Mounjaro nor Zepbound appears on any group.

Income limits, for reference if Lilly ever adds them, are 300% of the federal poverty level for Group 1, 400% for Group 2 and 500% for Groups 3 and 4. For Group 2 in 2026 that is $63,840 for one person and $132,000 for a household of four [13].

Lilly Cares also excludes anyone enrolled in Medicaid, full Extra Help or VA benefits, and anyone whose plan directs them to apply as a condition of coverage.

Why does Zepbound cost less for the same molecule?

Mounjaro and Zepbound are both tirzepatide, made by Eli Lilly, in the same six strengths. The difference is the approved use, and with it, two entirely separate commercial programs.

	Mounjaro	Zepbound
FDA-approved for	Type 2 diabetes; and, since August 28, 2026, reducing major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk	Chronic weight management; moderate-to-severe obstructive sleep apnea with obesity
List price	$1,112.16 per fill	$499 to $1,086.37 per fill
LillyDirect self-pay	“Starting at $499/month,” shown at every strength	$299 / $399 / $449 by dose
TrumpRx price	$499	$299 (vial)
Savings card, covered plan	As little as $25	As little as $25
Part D coverage	Yes, for type 2 diabetes	Only for sleep apnea, plus the GLP-1 Bridge

At the entry dose the same molecule costs $200 more as Mounjaro than as Zepbound. That is a pricing decision attached to the indication, not a difference in the drug.

What it is not is a shopping choice. Which brand you can be prescribed depends on your diagnosis. Asking a prescriber to code a diagnosis you do not have, to reach a lower price, is not a route this site will describe, and it can also void coverage and savings-card eligibility.

How does the US price compare internationally?

Badly, though the gap has narrowed.

The Peterson-KFF comparison put a month of Mounjaro at $1,023 in the US versus $444 in the Netherlands and $319 in Japan, using June 2023 exchange rates [2]. That table is dated and no public 2026 refresh has been published, but the direction has not reversed.

More recent national figures: Canada’s Patented Medicine Prices Review Board caps patented drug prices, and Canadian cash prices in 2026 run roughly CAD 280 to CAD 650 per month by dose and province, with Ontario’s formulary price reported at CAD 342 for a four-dose 2.5 mg pen [14]. Japanese self-pay clinics advertise roughly JPY 12,500 to JPY 15,100 a month for 2.5 mg.

In the UK, where Mounjaro is the brand used for both diabetes and weight management, Lilly raised list prices from September 1, 2025, taking the 15 mg pen from GBP 122 to GBP 330, and the NHS redetermined reimbursement prices to match. Even after that increase, UK prices are well below the US list.

Is a cheaper generic coming?

Not this decade, on the current record.

The core composition-of-matter patent on tirzepatide, US 9,474,780, expires May 13, 2036, with later-listed formulation, device and method-of-use patents running to 2039 and 2041 [15]. Tirzepatide’s New Chemical Entity exclusivity runs to May 13, 2027.

Sandoz announced FDA acceptance of its generic tirzepatide applications on June 29, 2026, and Amneal with Adalvo on July 8, 2026. Both sets of filings are for the single-dose autoinjector presentation. Acceptance for review is not approval, and an approved generic still cannot launch while patents stand.

The short version

Situation	What you pay
Commercial insurance that covers Mounjaro	As little as $25 with the savings card, capped at $150/month and $1,950/year
Commercial insurance that does not cover it	As low as $499/month via the card’s second tier
No insurance, want the real thing	From $499/month through LillyDirect, which is where TrumpRx sends you
Medicare Part D, type 2 diabetes	Plan copay, capped by the $2,100 annual out-of-pocket limit
Medicaid, type 2 diabetes	Nominal copay; coverage is federally required
TRICARE Prime/Select, type 2 diabetes	Covered with prior authorization
Walk-in retail, no coupon	Roughly $1,000 to $1,350

Before you assume any of these applies to you, call the number on your insurance card and ask two questions: is Mounjaro on my formulary, and does it require prior authorization? Those two answers decide which column you are in.

Sources

1. Eli Lilly, Mounjaro Cost Information: https://pricinginfo.lilly.com/mounjaro
2. Peterson-KFF Health System Tracker, prices of drugs for weight loss in the US and peer nations: https://www.healthsystemtracker.org/brief/prices-of-drugs-for-weight-loss-in-the-us-and-peer-nations/
3. Eli Lilly, second-quarter 2026 financial results: https://investor.lilly.com/news-releases/news-release-details/lilly-reports-second-quarter-2026-financial-results-raises-full
4. LillyDirect, Mounjaro: https://www.lilly.com/lillydirect/mounjaro
5. TrumpRx.gov, Mounjaro: https://trumprx.gov/p/mounjaro
6. Eli Lilly, Lilly and US government agree to expand access to obesity medicines: https://investor.lilly.com/news-releases/news-release-details/lilly-and-us-government-agree-expand-access-obesity-medicines
7. GoodRx, Mounjaro coupons and costs: https://www.goodrx.com/mounjaro
8. SingleCare, how to save on Mounjaro: https://www.singlecare.com/blog/mounjaro-savings/
9. Eli Lilly, Mounjaro savings and coverage: https://mounjaro.lilly.com/savings-coverage
10. CMS, BALANCE Model: https://www.cms.gov/priorities/innovation/innovation-models/balance
11. KFF, Medicaid coverage of and spending on GLP-1s: https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
12. TRICARE, coverage of weight loss medications: https://newsroom.tricare.mil/News/TRICARE-News/Article/4266447/tricare-coverage-of-weight-loss-medications-what-to-know
13. Lilly Cares Foundation, patient assistance program application and medication groups: https://www.lillycares.com/assets/pdf/lilly_cares_application.pdf and https://www.lillycares.com/how-to-apply
14. TeleTest, Mounjaro price in Canada: https://teletest.ca/cost/drug/mounjaro/
15. FDA Orange Book patent and exclusivity data for Mounjaro (NDA 215866): https://www.accessdata.fda.gov/scripts/cder/ob/patent_info.cfm?Product_No=001&Appl_No=215866&Appl_type=N
16. Eli Lilly, FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, August 28, 2026: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular